Research Study

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
Principal Investigator 
Sandra Sirrs

Overview

Disorders and Conditions 
ClinicalTrials.gov# 
NCT01298141
Status 
Recruiting
Study Start/End 
Apr 29, 2011 to Jun 30, 2017
Locations 
Vancouver General Hospital
Name/Title 
Anita Thomas, Research Assistant
Phone 
604-875-3806
Email Address 
athomas2@cw.bc.ca
Purpose of Study 

The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients with Fabry disease.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.